Skip to main content
. 2020 Feb 10;10(7):3049–3063. doi: 10.7150/thno.42385

Figure 4.

Figure 4

In vivo therapeutic effects and immune Activation of the MRK hydrogel. (A) Photograph of dissected tumor samples in different groups as indicated. (B) Tumor growth curves for mice injected intratumorally with PBS, MR52, KN93, or MRK hydrogel. Data are presented as the mean ± SEM (n = 7-8). (C) Representative bioluminescence images of B16F10 tumors in C57BL/6 mice after various treatments as indicated. (D) Quantification of tumor weights in each group. Data are presented as the mean ± SEM (n = 7-8). (E) Flow cytometry gating strategy for the detection ratio of macrophages. (F-G) Percentages of the M2/total macrophages (F) and M1/M2 ratios (G) within the TME of various treatment groups (M1-like TAMs: ZIR-CD11b+F4/80+CD86+CD206-, M2-like TAMs: ZIR-CD11b+F4/80+CD86-CD206+). (H) Percentages of activated DCs (CD11c+CD86+) within ILNs. (I) Ratios of CD45+ lymphocytes within the TME in each group. (J) Percentages of CD4+IFNγ+ T cells (Th1 cells) within the TME in each group. (K) Portions of cytotoxic CD8+IFNγ+ T cells (CTLs) within the TME in each group. Data are presented as the mean ± SEM (n = 8) for (F-K).